These findings validate Tim-3 as a promising therapeutic target in MDS and AML [106].The Phase I trial of the combination of MBG453 with decitabine or azacitidine reported the outcomes of 106 patients with high or very high-risk MDS (n = 34) or ND or R/R AML (n = 72). This evidence concerns the gene HAVCR2 and myelodysplastic syndrome.